Literature DB >> 19027033

Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin.

Jennifer M Bratt1, Lisa M Franzi, Angela L Linderholm, Michael S Last, Nicholas J Kenyon, Jerold A Last.   

Abstract

Arginase has been suggested to compete with nitric oxide synthase (NOS) for their common substrate, l-arginine. To study the mechanisms underlying this interaction, we compared arginase expression in isolated airways and the consequences of inhibiting arginase activity in vivo with NO production, lung inflammation, and lung function in both C57BL/6 and NOS2 knockout mice undergoing ovalbumin-induced airway inflammation, a mouse model of asthma. Arginases I and II were measured by western blot in isolated airways from sensitized C57BL/6 mice exposed to ovalbumin aerosol. Physiological and biochemical responses - inflammation, lung compliance, airway hyperreactivity, exhaled NO concentration, arginine concentration - were compared with the responses of NOS2 knockout mice. NOS2 knockout mice had increased total cells in lung lavage, decreased lung compliance, and increased airway hyperreactivity. Both arginase I and arginase II were constitutively expressed in the airways of normal C57BL/6 mice. Arginase I was up-regulated approximately 8-fold in the airways of C57BL/6 mice exposed to ovalbumin. Expression of both arginase isoforms were significantly upregulated in NOS2 knockout mice exposed to ovalbumin, with about 40- and 4-fold increases in arginases I and II, respectively. Arginine concentration in isolated airways was not significantly different in any of the groups studied. Inhibition of arginase by systemic treatment of C57BL/6 mice with a competitive inhibitor, Nomega-hydroxy-nor-l-arginine (nor-NOHA), significantly decreased the lung inflammatory response to ovalbumin in these animals. We conclude that NOS2 knockout mice are more sensitive to ovalbumin-induced airway inflammation and its sequelae than are C57BL/6 mice, as determined by increased total cells in lung lavage, decreased lung compliance, and increased airway hyperreactivity, and that these findings are strongly correlated with increased expression of both arginase isoforms in the airways of the NOS2 knockout mice exposed to ovalbumin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027033      PMCID: PMC2666129          DOI: 10.1016/j.taap.2008.10.007

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  31 in total

1.  A major susceptibility gene for asthma maps to chromosome 14q24.

Authors:  Hakon Hakonarson; Unnur S Bjornsdottir; Eva Halapi; Snaebjorn Palsson; Elva Adalsteinsdottir; David Gislason; Gudmundur Finnbogason; Thorarinn Gislason; Kristleifur Kristjansson; Thor Arnason; Illugi Birkisson; Michael L Frigge; Augustine Kong; Jeffrey R Gulcher; Kari Stefansson
Journal:  Am J Hum Genet       Date:  2002-07-15       Impact factor: 11.025

Review 2.  Arginase: marker, effector, or candidate gene for asthma?

Authors:  Donata Vercelli
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

3.  Activities of arginase I and II are limiting for endothelial cell proliferation.

Authors:  Hui Li; Cynthia J Meininger; Katherine A Kelly; James R Hawker; Sidney M Morris; Guoyao Wu
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-01       Impact factor: 3.619

4.  Regulation of ciliary beat frequency by the nitric oxide-cyclic guanosine monophosphate signaling pathway in rat airway epithelial cells.

Authors:  D Li; G Shirakami; X Zhan; R A Johns
Journal:  Am J Respir Cell Mol Biol       Date:  2000-08       Impact factor: 6.914

5.  Susceptibility to ozone-induced acute lung injury in iNOS-deficient mice.

Authors:  Nicholas J Kenyon; Albert van der Vliet; Bettina C Schock; Tatsuya Okamoto; Gabrielle M McGrew; Jerold A Last
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-03       Impact factor: 5.464

6.  Viral induction of a chronic asthma phenotype and genetic segregation from the acute response.

Authors:  Michael J Walter; Jeffrey D Morton; Naohiro Kajiwara; Eugene Agapov; Michael J Holtzman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

7.  Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences.

Authors:  Nicholas J Kenyon; Jennifer M Bratt; Angela L Linderholm; Michael S Last; Jerold A Last
Journal:  Toxicol Appl Pharmacol       Date:  2008-03-15       Impact factor: 4.219

8.  Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis.

Authors:  Nives Zimmermann; Nina E King; Johanne Laporte; Ming Yang; Anil Mishra; Sam M Pope; Emily E Muntel; David P Witte; Anthony A Pegg; Paul S Foster; Qutayba Hamid; Marc E Rothenberg
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

9.  Airway fibrosis in a mouse model of airway inflammation.

Authors:  Nicholas J Kenyon; Rachel W Ward; Jerold A Last
Journal:  Toxicol Appl Pharmacol       Date:  2003-01-15       Impact factor: 4.219

10.  Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox.

Authors:  Junghee Lee; Hoon Ryu; Robert J Ferrante; Sidney M Morris; Rajiv R Ratan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

View more
  26 in total

1.  Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?

Authors:  Amir A Zeki; Jennifer M Bratt; Michelle Rabowsky; Jerold A Last; Nicholas J Kenyon
Journal:  Transl Res       Date:  2010-12       Impact factor: 7.012

Review 2.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  l-Arginine supplementation in severe asthma.

Authors:  Shu-Yi Liao; Megan R Showalter; Angela L Linderholm; Lisa Franzi; Celeste Kivler; Yao Li; Michael R Sa; Zachary A Kons; Oliver Fiehn; Lihong Qi; Amir A Zeki; Nicholas J Kenyon
Journal:  JCI Insight       Date:  2020-07-09

4.  2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.

Authors:  Monica Ilies; Luigi Di Costanzo; Michelle L North; Jeremy A Scott; David W Christianson
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

5.  Why is particulate matter produced by wildfires toxic to lung macrophages?

Authors:  Lisa M Franzi; Jennifer M Bratt; Keisha M Williams; Jerold A Last
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-16       Impact factor: 4.219

Review 6.  Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease.

Authors:  Cleva Villanueva; Cecilia Giulivi
Journal:  Free Radic Biol Med       Date:  2010-04-11       Impact factor: 7.376

7.  Nitric oxide synthase enzymes in the airways of mice exposed to ovalbumin: NOS2 expression is NOS3 dependent.

Authors:  Jennifer M Bratt; Keisha Williams; Michelle F Rabowsky; Michael S Last; Lisa M Franzi; Jerold A Last; Nicholas J Kenyon
Journal:  Mediators Inflamm       Date:  2010-10-05       Impact factor: 4.711

Review 8.  Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.

Authors:  Harm Maarsingh; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

9.  Dual oxidase regulates neutrophil recruitment in allergic airways.

Authors:  Sandra Chang; Angela Linderholm; Lisa Franzi; Nicholas Kenyon; Helmut Grasberger; Richart Harper
Journal:  Free Radic Biol Med       Date:  2013-06-11       Impact factor: 7.376

10.  Anti-inflammatory effect of arginase inhibitor and corticosteroid on airway allergic reactions in a Dermatophogoides farinae-induced NC/Nga mouse model.

Authors:  Keiki Ogino; Masayuki Kubo; Hidekazu Takahashi; Ran Zhang; Yu Zou; Yoshihisa Fujikura
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.